Johannes W. Heidbuechel
Heidelberg, BW, Germany
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
In silico clinical trials of BiTE expression by oncolytic viruses reveal the impact of patient heterogeneity on dosage protocol.
Journal: PLoS computational biology
Published: February 02, 2026
A measles virus encoding a CD19/CD3 bispecific T cell engager shows enhanced preclinical anti-BCP-ALL efficacy without significant toxicity.
Journal: Molecular therapy. Oncology
Published: May 02, 2025
Oncolytic viruses encoding bispecific T cell engagers: a blueprint for emerging immunovirotherapies.
Oncolytic viruses encoding bispecific T cell engagers: a blueprint for emerging immunovirotherapies.
Journal: Journal of hematology & oncology
Published: December 06, 2020
Measles Vaccines Designed for Enhanced CD8+ T Cell Activation.
Journal: Viruses
Published: December 20, 2019
Mathematical Modeling of Oncolytic Virotherapy.
Journal: Methods in molecular biology (Clifton, N.J.)
Published: September 06, 2019
Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo.
Journal: Journal of visualized experiments : JoVE
Published: January 22, 2019
Targeted BiTE Expression by an Oncolytic Vector Augments Therapeutic Efficacy Against Solid Tumors.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: September 11, 2017
Showing 1-9 of 9
Last Updated: 09/26/2026